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New spirometry? The 2019 update of the test standardization
Introduction
Spirometry is a commonly performed assess-
ment of lung function for diagnostic purposes as 
well as  for monitoring of chronic lung diseases. 
The last international standardization of this 
study was published in 2005 [1], and the Polish 
version of the recommendations appeared a year 
later [2]. After 14 years, a group of experts from 
two leading scientific societies, ATS (American 
Thoracic Society) and ERS (European Respiratory 
Society), published a joint position that updated 
the standardization of spirometry [3]. There are 
essentially no significant changes to the test tech-
nique, but there have been some modifications 
regarding the circumstances surrounding the 
test and the assessment of the maneuvers. Due 
to the short nature of this article, the reader will 
find below information on selected and, in the 
authors’ opinion, the most important key changes 
compared to the standards being in use for the 
last 14 years.
Contraindications for spirometry
Spirometry is generally a safe procedure, as 
demonstrated by many years of experience and 
publications in the literature. Adverse events 
occur at a frequency of 5/10,000 and are usually 
mild (syncope was most commonly observed). 
The risk of adverse events in spirometry is pri-
marily associated with significant fluctuations 
in chest pressures and their impact on the ab-
dominal and thoracic organs, venous return and 
systemic blood pressure. Therefore, caution must 
be used for patients with medical conditions that 
could be adversely affected by these physiological 
consequences. The ATS/ERS recommendations 
on spirometry published at the end of 2019 give 
all contraindications with the status of “relative” 
and list the following situations requiring special 
attention (consider the appropriateness of per-
forming the test):
— Due to increases in myocardial demand or 
changes in blood pressure
• Acute myocardial infarction within 1 wk
• Systemic hypotension or severe hyper-
tension
• Significant atrial/ventricular arrhythmia
• Noncompensated heart failure
• Uncontrolled pulmonary hypertension
• Acute cor pulmonale
• Clinically unstable pulmonary embolism
• History of syncope related to forced expi-
ration/cough
— Due to increases in intracranial/intraocular 
pressure
• Cerebral aneurysm
• Brain surgery within 4 wk
• Recent concussion with continuing symp-
toms
• Eye surgery within 1 wk
— Due to increases in sinus and middle ear 
pressures
• Sinus surgery or middle ear surgery or 
infection within 1 wk
— Due to increases in intrathoracic and intraab-
dominal pressure
• Presence of pneumothorax
• Thoracic surgery within 4 wk
• Abdominal surgery within 4 wk
• Late-term pregnancy
Advances in Respiratory Medicine 2020, vol. 88, no. 2, pages 95–98
96 www.journals.viamedica.pl
— Infection control issues
• Active or suspected transmissible res-
piratory or systemic infection, including 
tuberculosis
• Physical conditions predisposing to trans-
mission of infections, such as hemoptysis, 
significant secretions,  oral lesions or oral 
bleeding.
It is worth noting that the presence of aortic 
aneurysms has ceased to be a contraindication. 
Spirometry should always be interrupted if pain 
occurs during maneuvers. Relative contraindi-
cations do not exclude the possibility of spiro-
metry, but they should be taken into account 
when referring the patient to this examination. 
Individuals with potential contraindications that 
would prevent an examination in primary care 
settings may be examined in more experienced 
centers and with the access to emergency care. 
The decision to perform spirometry is determined 
by the referring physician based on a  risk and 
benefit assessment for the individual patient. 
Potential contraindications should be provided 
on the referral form.
Equipment requirements
The most important change was adapting 
the standards to the requirements of the Inter-
national Organization for Standardization (ISO) 
standard number 26782 dated 2009, replacing 
the ATS standard curves with curves according 
to the mentioned requirements and narrowing 
the accuracy range to ± 2.5% in both: testing 
the spirometer using standard curves as well as 
checking calibration using a 3-liter calibration 
syringe. Information was also added about the 
required accuracy of the 3 L calibration syringe, 
which should be within ± 0.5%, what in practice 
gives the accuracy of the entire calibration pro-
cess at the current recommended level of ± 3%. 
Recommendations for daily checking/performing 
calibration indicate the need for maneuvers in 
a wide range of flows (from 0.5 to 12 L/s, i.e. pi-
ston movement lasting from 0.5 to 6 sec), which 
in practice also means checking the so-called 
linearity. It is also recommended to periodically 
check the calibration syringe for accuracy and 
monthly leak test.
Personnel qualifications
The relationship between the commitment 
and skills of the researcher and the quality of 
spirometry are emphasized. It is the responsibility 
of the person performing the study to observe the 
patient and interact with him in order to achieve 
optimal results. This requires a combination of 
skills acquired during training and experience that 
comes with the time and number of performed tests. 
Patient’s data
It is obvious that the correct person’s anthro-
pometric data should be obtained and, for this 
purpose, appropriate height and weight measure-
ments taken. Current standards specify the degree 
of accuracy for individual values (age and height to 
1 decimal place, weight to the nearest 0.5 kg). Gen-
der and belonging to an ethnic group at birth, not 
declared by the patient, should be used to calculate 
predicted values. In the absence of these data, the 
person interpreting the result should be notified. 
The list of behaviors to be avoided before spirom-
etry testing was modified: smoking electronic ciga-
rettes (vaping) and consumption of intoxicants (to 
avoid problems with coordination, understanding 
and physical performance) were added.
Spirometry measurements
Values of FEV1 (forced expiratory volume at 
the first second of exhalation), FVC (forced vital 
capacity) and their ratio FEV1/FVC expressed 
as a  fraction (or less correctly as a percentage) 
called the Tiffeneau index still remain crucial for 
the spirometry test result. However, it is worth 
noting that the current standards also indicate an 
important role (and recommend performing) of 
the measurement of the FIVC (forced inspiratory 
vital capacity) maneuver after the FVC maneuver 
in order to verify the correctness of the inspiration 
preceding the forced exhalation. For this reason, 
spirometers measuring only expiratory volumes (in 
practice no longer employed) should not be used. 
An important change is the redefinition of 
a technically correct (acceptable) forced expira-
tion maneuver and the associated introduction of 
the concept of a maneuver technically unaccept-
able but clinically useful.
A forced expiratory maneuver is considered as 
technically correct if the following criteria are met:
— sufficiently fast onset of exhalation as in-
dicated by BEV (back extrapolated volume) 
< 5% of FVC or < 100 mL, whichever is greater;
— no artifacts (e.g. coughing, closing the glottis, 
incomplete breathing effort);
— one of the criteria for successful completion 
of the maneuver was achieved in the follow-
ing hierarchy:
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Table 1. Grading System for FEV1 and FVC (graded separately)
Grade Number of measurements Repeatability:  
Age > 6 years
Repeatability:  
Age ≤ 6 years
A ≥ 3 acceptable ≤ 0.15 L ≤0.1 L*
B 2 acceptable ≤ 0.15 L ≤0.1 L*
C ≥ 2 acceptable ≤ 0.2 L ≤0.15 L*
D ≥ 2 acceptable ≤ 0.25 L ≤0.2 L*
E ≥ 2 acceptable 
OR 1 acceptable
> 0.25 L
N/A
>0.2 L*
N/A
U 0 acceptable AND ≥ 1 usable N/A N/A
F 0 acceptable AND 0 usable N/A N/A
*Or 10% of the highest value, whichever is greater; applies for age 6 years or younger only. FEV1 — forced expiratory volume at the first second of exhalation; FVC — 
forced vital capacity; N/A — not applicable
• a plateau was reached on the volume-time 
curve (volume change at last second exha-
lation < 25 mL);
• exhalation continuously lasted 15 seconds;
• satisfactory FVC repeatability has been 
obtained or the FVC measured last is bigger 
than the best so far (in the same session).
If FIVC is correctly recorded, then the inspi-
ratory — expiratory differences (FIVC — FVC) 
should not be greater than 100 mL or 5% of FVC. 
If satisfactory reproducibility is not achieved 
(the differences between the 2 best FVC and 
FEV1 results exceed 150 ml), it is recommended 
to repeat maneuvers, but no more than 8 forced 
exhalations should be performed during one 
measurement session.
It is worth noting that there is no longer striv-
ing for a minimum of 6 seconds of exhalation in 
cases where a plateau of the volume-time expira-
tory curve is previously reached. The recommen-
dations also mention about the time to reach PEF 
(peak expiratory flow), which should be as short as 
possible and usually should not exceed 0.15 sec, 
but this is not a mandatory criterion.
The “U” category has been added to the pre-
viously slightly modified thresholds of acceptable 
repeatability [4] — a useful result but not meeting 
the technical acceptability criteria. To simplify, 
these are maneuvers during which there is no 
doubt about the correct start, but none of the con-
ditions for successful completion can be achieved. 
Interpretation of such results is possible but has 
limited value, especially in the case of results in 
the abnormal range. A new scale was introduced 
regarding the quality of the spirometry test from 
the point of view of the degree of repeatability of 
results (A, B, C, D, E, U, F), in which FEV1 and FVC 
measurements are assessed separately (Table 1) [3].
Bronchodilator responsiveness testing 
The need to distinguish the concepts of 
reversibility of obstruction (defined as normal-
ization of the FEV1/FVC ratio) from the signifi-
cance of improvement (assessed as response in 
the FEV1 or FVC) and the necessity to unify the 
nomenclature in this area were pointed out. The 
list of drugs and the recommended time periods 
for which they should be discontinued before 
the test to check the reactivity of the airways to 
the bronchodilator have been updated. For drugs 
from the ultra-long-acting beta2-agonist group 
(e.g. indacaterol, vilanterol, olodaterol), the rec-
ommended time since the last dose is 36 hours, 
for long-acting muscarinic receptor antagonist 
(e.g. tiotropium, umeclidinium, aclidinium or 
glycopyronium), delay should be a bit longer, 
approx. 36–48 hours. It is worth noting that 
these periods are shorter than when preparing 
for methacholine challenge test because the 
protective effect of these drugs lasts longer than 
the bronchodilation effect.
There is also a recommendation that the first 
spirometry test performed for diagnostic purposes 
should always be accompanied by bronchodi-
lator responsiveness testing because the lack 
of airway obstruction in the baseline does not 
exclude possible significant improvement after 
bronchodilators. The recommendation seems to 
be justified from a purely substantive point of 
view, but the authors’ experience shows that  the 
“reversibility test” should not be the first spirom-
etry in the subject’s life because the effect of the 
drug may be superimposed on the learning effect 
and the improvement observed may be the result 
of a better technique rather than the effect of the 
real bronchodilation. 
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